Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019


#437866

78pages

Technavio

$ 2500

In Stock

About non-small cell lung cancer therapeutics
Non-small cell lung cancer occurs when normal cells grow and multiply without control after undergoing a cell transformation. Lung cancer is the leading cause of cancer deaths worldwide, and the incidence of lung cancer is increasing significantly. Lung cancer is the common cause of mortality and morbidity not only in developed countries but also in developing countries. One of the most common types of lung cancer is non-small cell lung cancer. It grows and spreads quite slowly. Smoking is considered as a major cause of lung cancer, although lung cancer also occurs in non-smokers. There are three main types of non-small cell lung cancer: squamous cell (epidermoid) carcinoma, adenocarcinoma, and large cell (undifferentiated) carcinoma. Some of the common symptoms associated with non-small cell lung cancer are chest pain, a cough that does not go away, coughing up blood, fatigue, loss of appetite, losing weight without trying, shortness of breath, and wheezing.

Technavio's analysts forecast the global non-small cell lung cancer therapeutics market to grow at a CAGR of 6.77% over the period 2014-2019.

Covered in this report
The report covers the current scenario and the growth prospects of the global non-small cell lung cancer therapeutics market for the period of 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used for the treatment of non-small cell lung cancer.

Technavio's report, Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and Europe; it also covers the landscape of the global non-small cell lung cancer therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions
Americas
APAC
Europe

Key vendors
AstraZeneca
Celgene
Eli Lilly
F. Hoffmann-La Roche
Pfizer

Other prominent vendors
Abbvie
Aetna
Agennix
Amgen
BetaPharma
Bionumerik Pharmaceuticals
Boehringer Ingelheim
Bristol-Myers Squibb
CBT Pharma
Celldex Therapeutics
Dainippon Pharma
Eisai Pharmaceuticals
GlaxoSmithKline
Helsinn
IMClone Systems
IsisPharma
Kadmon
Kyowa Hakko Kirin
MabVax Therapeutics
Merck
Novartis
OncoGenex
OSI Pharmaceuticals
Peregrine
Pierre Fabre
Qiagen
Sanofi
Synta Pharmaceuticals
Teva Pharmaceuticals


Key market driver
Promising drug pipeline
For a full, detailed list, view our report

Key market challenge
High cost of therapy
For a full, detailed list, view our report

Key market trend
Personalized medicine
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2019 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?